[Metronidazole in the treatment and prevention of infections in gynecology and obstetrics].
Metronidazole which has been widely used in the treatment of trichomoniasis urogenitalis is the most active agent available against obligate anaerobes.--In this review the present data about antimicrobial activity, mode of action, pharmacokinetic behaviour, dosage, clinical use in gynecology and obstetrics and side effects of metronidazole are outlined.
D001424:Bacterial Infections / Q000188:drug therapy; D001711:Biotransformation; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D008657:Metabolic Clearance Rate; D008795:Metronidazole / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*; D014247:Trichomonas Vaginitis / Q000188:drug therapy*; D014627:Vaginitis / Q000188:drug therapy
D008795:Metronidazole
Metronidazol bei der Behandlung und Prophylaxe von Infektionen in der Gynäkologie und Geburtshilfe.